Iradimed Co (IRMD)vsJohnson & Johnson (JNJ)
IRMD
Iradimed Co
$83.93
-0.02%
HEALTHCARE · Cap: $1.13B
JNJ
Johnson & Johnson
$271.17
+0.86%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 114954% more annual revenue ($99.33B vs $86.34M). IRMD leads profitability with a 26.7% profit margin vs 16.2%. JNJ appears more attractively valued with a PEG of 2.82. JNJ earns a higher WallStSmart Score of 57/100 (C).
IRMD
Hold48
out of 100
Grade: D+
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.0%
Fair Value
$61.71
Current Price
$83.93
$22.22 premium
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$271.17
$127.05 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Keeps 27 of every $100 in revenue as profit
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Areas to Watch
Trading at 10.5x book value
0.3% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 26.7% and operating margin at 31.2%.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Revenue Growth, Market Cap. A P/E of 49.3x leaves little room for execution misses.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
IRMD profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
IRMD carries more volatility with a beta of 0.91 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 48/100), backed by strong 16.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?